Loading...
CSCI.D logo

COSCIENS Biopharma Inc.OTCPK:CSCI.D Stock Report

Market Cap US$5.7m
Share Price
n/a
1Y-53.7%
7D-4.3%
1D1.9%
Portfolio Value
​
View

COSCIENS Biopharma Inc.

OTCPK:CSCI.D Stock Report

Market Cap: US$5.7m

COSCIENS Biopharma (CSCI.D) Stock Overview

A life science company, develops and commercializes products for the cosmeceutical, nutraceutical and pharmaceutical markets in the United States, Germany, the United Kingdom, and internationally. More details

CSCI.D fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health4/6
Dividends0/6

Risk Analysis

Has less than 1 year of cash runway

Does not have a meaningful market cap ($6M)

Earnings have declined by 8.9% per year over past 5 years

Volatile share price over the past 3 months compared to the US market


CSCI.D Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW480,107 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.
Grow your followingReal investors. The kind who actually invest, not scroll past.
Unlock free accessFree premium subscription for consistent and quality authors.
Learn moreCreate Narrative
BL
BlackGoat
IN
Investingwilly
RO
RockeTeller
DA
davidlsander
480,107 investors already sharing narratives
View all narratives

COSCIENS Biopharma Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for COSCIENS Biopharma
Historical stock prices
Current Share PriceCA$5.50
52 Week HighCA$12.21
52 Week LowCA$2.37
Beta1.9
1 Month Change-12.70%
3 Month Change-5.98%
1 Year Change-53.70%
3 Year Change-84.77%
5 Year Change-97.47%
Change since IPO-99.90%

Recent News & Updates

Recent updates

Seeking Alpha • Aug 29

Aeterna Zentaris to regain full rights to Macrilen oral test from Novo Nordisk

Aeterna Zentaris (NASDAQ:AEZS) on Monday said it would regain the U.S. and Canadian rights for Macrilen, an oral test to detect adult growth hormone deficiency, from Danish pharmaceutical company Novo Nordisk (NVO). The company said it would get the rights back after NVO decided to terminate the amended development and commercialization licensing agreement between the two parties. NVO will have a 270-day notice period in which it will continue to sell and promote Macrilen in the U.S. "In light of Novo Nordisk’s decision, Aeterna plans to engage in robust business development efforts to identify and secure a new development and commercialization partner," AEZS said in a statement. AEZS stock -1.8% to $5 in morning trading.
Seeking Alpha • Jul 19

Aeterna slips ~10% after announcing date of reverse stock split

The shares of the commercial-stage biotech Aeterna Zentaris (NASDAQ:AEZS) dropped ~10% in the morning hours Tuesday after the company disclosed that its previously announced 1-25 reverse stock split would take effect this week. Accordingly, the common shares of Aeterna (AEZS) will start trading on a split-adjusted basis on or about the opening of trading on July 21. The consolidation is expected to reduce the issued and outstanding common shares to ~4.9M from ~121.4M, Aeterna (AEZS) said. The reverse stock split is aimed at meeting the Nasdaq’s minimum bid price requirement to keep the minimum bid price above US$1.00 for a minimum of at least ten consecutive days. However, the company is unlikely to satisfy the listing rule before July 25, the current expiration date of its grace period. A potential notice of delisting during that week will give seven calendar days for Aeterna (AEZS) to request a hearing. The company expects to regain compliance by August 03 following the reverse stock split. In mid-July, Aeterna (AEZS) obtained shareholder approval for the proposed share consolidation.

Shareholder Returns

CSCI.DUS BiotechsUS Market
7D-4.3%-1.4%-1.4%
1Y-53.7%28.1%16.4%

Return vs Industry: CSCI.D underperformed the US Biotechs industry which returned 28.1% over the past year.

Return vs Market: CSCI.D underperformed the US Market which returned 16.4% over the past year.

Price Volatility

Is CSCI.D's price volatile compared to industry and market?
CSCI.D volatility
CSCI.D Average Weekly Movement11.5%
Biotechs Industry Average Movement10.2%
Market Average Movement7.1%
10% most volatile stocks in US Market16.3%
10% least volatile stocks in US Market3.2%

Stable Share Price: CSCI.D's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: CSCI.D's weekly volatility has decreased from 17% to 12% over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
199028Peter Puccettiwww.cosciensbio.com

COSCIENS Biopharma Inc., a life science company, develops and commercializes products for the cosmeceutical, nutraceutical and pharmaceutical markets in the United States, Germany, the United Kingdom, and internationally. It operates through Active Ingredient and Pharmaceutical segments. The company offers active ingredients comprising oat beta glucan, a functional ingredient that supports overall health and wellness; oat powder and peptides; oat oil which is extracted from whole oat kernels by a gentle process that retains all the important biologically active components; and avenanthramides, a natural-based ingredients used to inflammation-based diseases for the cosmeceutical and pharmaceutical industries.

COSCIENS Biopharma Inc. Fundamentals Summary

How do COSCIENS Biopharma's earnings and revenue compare to its market cap?
CSCI.D fundamental statistics
Market capUS$5.74m
Earnings (TTM)-US$7.87m
Revenue (TTM)US$8.00m
0.7x
P/S Ratio
-0.7x
P/E Ratio

Is CSCI.D overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
CSCI.D income statement (TTM)
RevenueUS$8.00m
Cost of RevenueUS$5.00m
Gross ProfitUS$3.00m
Other ExpensesUS$10.86m
Earnings-US$7.87m

Last Reported Earnings

Mar 31, 2026

Next Earnings Date

n/a

Earnings per share (EPS)-7.41
Gross Margin37.44%
Net Profit Margin-98.35%
Debt/Equity Ratio0%

How did CSCI.D perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/23 23:27
End of Day Share Price 2026/07/23 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

COSCIENS Biopharma Inc. is covered by 11 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Douglas LoeCantor Fitzgerald Canada Corporation
Charles DuncanCitizens JMP Securities, LLC
Pooya HemamiDesjardins Securities Inc.